A Phase 3 interventional study of CT-P43 and Stelara in Psoriasis, sponsored by Celltrion. Completed at 1 site in Estonia. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-06-05.
Sponsored by Celltrion · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Psoriasis with a site in Estonia — none open to participants now, 1 under way, 1 of them phase 3. Psoriasis · Estonia.
Among the 33 studies in Psoriasis with a site in Estonia, this one is the 12th largest by enrollment of the 32 interventional ones that give a count, is one of 6 that started in 2021, is one of 27 in phase 3, and was the 24th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →None of the 33 studies in Psoriasis with a site in Estonia is open now. The open studies under Psoriasis, anywhere →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 509 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 434 across the 32 interventional studies, 506 across the 1 observational. Of the 32 that completed or were terminated, 25 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 33 have an industry lead sponsor. The 10 most frequent:
Celltrion is the lead sponsor of 77 studies on the registry; 2 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 14 (74%) have results posted.
Celltrion has 4 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 33 studies in Psoriasis with a site in Estonia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a randomized, active-controlled, double-blind, phase 3 study to compare the efficacy and safety of CT-P43 to Stelara in patients with moderate to severe plaque psoriasis.
CT-P43, containing the active ingredient ustekinumab, is a human IgG1κ monoclonal antibody that is being developed as a biosimilar medicinal product to the reference product, Stelara. The purpose of this study is to demonstrate similar efficacy and safety of CT-P43 and Stelara in patients with moderate to severe plaque psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients who were initially randomized to the CT-P43 group on Day 1 (Week 0) will continue their treatment with CT-P43 until Week 40.
Biological: CT-P43
Patients who were initially randomized to Stelara group on Day 1 (Week 0) will be randomized again in a ratio of 1:1 to either continue Stelara or undergo transition to CT-P43 prior to dosing at Week 16. Thereafter, patients will continue their treatment until Week 40.
Biological: CT-P43 · Biological: Stelara
45mg or 90mg dose subcutaneous administration
45mg or 90mg dose subcutaneous administration
The Mean Percent Improvement From Baseline in PASI Score at Week 12
The percent improvement from baseline in Psoriasis Area and Severity Index (PASI) score at Week 12. PASI score can range from 0 (no psoriasis) to 72 (severe psoriasis).
Time frame: From baseline to Week 12
The PASI Scores at Week 12
The Psoriasis Area and Severity Index (PASI) score at Week 12. PASI score can range from 0 (no psoriasis) to 72 (severe psoriasis).
Time frame: Week 12
The Mean Percent Improvement From Baseline in PASI Score Through Week 52
The percent improvement from baseline in Psoriasis Area and Severity Index (PASI) score through Week 52. PASI score can range from 0 (no psoriasis) to 72 (severe psoriasis).
Time frame: Through Week 52
The Number of Patients Achieving PASI 50, PASI 75, PASI 90, and PASI 100 Responses at Week 12
The number of participants achieving at least 50%/75%/90%/100% improvement from baseline in Psoriasis Area and Severity Index (PASI) at Week 12. PASI score can range from 0 (no psoriasis) to 72 (severe psoriasis).
Time frame: Week 12
The Number of Patients With sPGA Score of Clear (0) or Almost Clear (1) at Week 12
The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the erythema, average thickness, and scaling of all psoriatic lesions at a given time point. The sum of the 3 scales will be divided by 3 to obtain a final sPGA score.
Time frame: Week 12
The Change From Baseline in Dermatology Life Quality Index (DLQI) Through Week 52
This DLQI is a 10-item patient-reported outcome questionnaire that, in addition to evaluating overall QoL, can be used to assess 6 different aspects that may affect QoL: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Total scores range from 0 to 30 (less to more impairment).
Time frame: Through Week 52
| Milestone | CT-P43 | EU-Stelara | Switched to CT-P43 |
|---|---|---|---|
| Started | 256 | 253 | 0 |
| Completed | 253 | 249 | 0 |
| Not completed | 3 | 4 | 0 |
| Withdrew: Withdrawal by subject | 3 | 3 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Milestone | CT-P43 | EU-Stelara | Switched to CT-P43 |
|---|---|---|---|
| Started | 253 | 125 | 124 |
| Completed | 239 | 122 | 122 |
| Not completed | 14 | 3 | 2 |
| Withdrew: Withdrawal by subject | 9 | 3 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 1 |
The percent improvement from baseline in Psoriasis Area and Severity Index (PASI) score at Week 12. PASI score can range from 0 (no psoriasis) to 72 (severe psoriasis).
| percentage of improvement in PASI score | CT-P43 | EU-Stelara |
|---|---|---|
| The Mean Percent Improvement From Baseline in PASI Score at Week 12 | 77.93 ± 1.771 | 75.89 ± 1.739 |
The Psoriasis Area and Severity Index (PASI) score at Week 12. PASI score can range from 0 (no psoriasis) to 72 (severe psoriasis).
| score on a scale | CT-P43 | EU-Stelara |
|---|---|---|
| The PASI Scores at Week 12 | 2.98 ± 3.412 | 3.44 ± 4.362 |
The percent improvement from baseline in Psoriasis Area and Severity Index (PASI) score through Week 52. PASI score can range from 0 (no psoriasis) to 72 (severe psoriasis).
| percentage of improvement in PASI score | CT-P43 Maintenance | EU-Stelara Maintenance | Switched to CT-P43 |
|---|---|---|---|
| The Mean Percent Improvement From Baseline in PASI Score Through Week 52 | 93.79 ± 11.794 | 93.39 ± 14.947 | 91.58 ± 13.264 |
The number of participants achieving at least 50%/75%/90%/100% improvement from baseline in Psoriasis Area and Severity Index (PASI) at Week 12. PASI score can range from 0 (no psoriasis) to 72 (severe psoriasis).
| Participants | CT-P43 | EU-Stelara |
|---|---|---|
| PASI 50 | 247 | 240 |
| PASI 75 | 212 | 187 |
| PASI 90 | 129 | 127 |
| PASI 100 | 47 | 48 |
The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the erythema, average thickness, and scaling of all psoriatic lesions at a given time point. The sum of the 3 scales will be divided by 3 to obtain a final sPGA score.
| Participants | CT-P43 | EU-Stelara |
|---|---|---|
| The Number of Patients With sPGA Score of Clear (0) or Almost Clear (1) at Week 12 | 219 | 201 |
This DLQI is a 10-item patient-reported outcome questionnaire that, in addition to evaluating overall QoL, can be used to assess 6 different aspects that may affect QoL: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Total scores range from 0 to 30 (less to more impairment).
| score on a scale | CT-P43 Maintenance | EU-Stelara Maintenance | Switched to CT-P43 |
|---|---|---|---|
| The Change From Baseline in Dermatology Life Quality Index (DLQI) Through Week 52 | -10.5 ± 7.24 | -8.5 ± 7.17 | -9.2 ± 6.93 |
Collected over Through 52 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Period I: CT-P43 | 0/256 (0%) | 4/256 (1.6%) | 14/256 (5.5%) |
| Treatment Period I: EU-Stelara | 0/253 (0%) | 4/253 (1.6%) | 20/253 (7.9%) |
| Treatment II: CT-P43 Maintenance | 1/253 (0.4%) | 5/253 (2%) | 35/253 (13.8%) |
| Treatment Period II: EU-Stelara Maintenance | 0/125 (0%) | 3/125 (2.4%) | 25/125 (20%) |
| Treatment Period II: Switched to CT-P43 | 0/124 (0%) | 2/124 (1.6%) | 28/124 (22.6%) |
| Event | Treatment Period I: CT-P43 | Treatment Period I: EU-Stelara | Treatment II: CT-P43 Maintenance | Treatment Period II: EU-Stelara Maintenance | Treatment Period II: Switched to CT-P43 |
|---|---|---|---|---|---|
| NephrolithiasisRenal and urinary disorders | 0/256 | 0/253 | 0/253 | 0/125 | 1/124 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/256 | 0/253 | 0/253 | 0/125 | 1/124 |
| COVID-19 pneumoniaInfections and infestations | 2/256 | 1/253 | 0/253 | 1/125 | 0/124 |
| COVID-19Infections and infestations | 0/256 | 0/253 | 0/253 | 1/125 | 0/124 |
| Guillain-Barre syndromeNervous system disorders | 0/256 | 0/253 | 0/253 | 1/125 | 0/124 |
| Subarachnoid haemorrhageNervous system disorders | 0/256 | 1/253 | 0/253 | 0/125 | 0/124 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/256 | 1/253 | 0/253 | 0/125 | 0/124 |
| Menstrual disorderReproductive system and breast disorders | 0/256 | 1/253 | 0/253 | 0/125 | 0/124 |
| Myocardial infarctionCardiac disorders | 0/256 | 0/253 | 1/253 | 0/125 | 0/124 |
| Pancreatitis acuteGastrointestinal disorders | 0/256 | 0/253 | 1/253 | 0/125 | 0/124 |
| Event | Treatment Period I: CT-P43 | Treatment Period I: EU-Stelara | Treatment II: CT-P43 Maintenance | Treatment Period II: EU-Stelara Maintenance | Treatment Period II: Switched to CT-P43 |
|---|---|---|---|---|---|
| COVID-19Infections and infestations | 11/256 | 12/253 | 13/253 | 11/125 | 7/124 |
| Upper respiratory tract infectionInfections and infestations | 3/256 | 8/253 | 10/253 | 4/125 | 7/124 |
| Alanine aminotransferase increasedInvestigations | 0/256 | 0/253 | 3/253 | 3/125 | 6/124 |
| Latent tuberculosisInfections and infestations | 0/256 | 0/253 | 7/253 | 4/125 | 4/124 |
| NasopharyngitisInfections and infestations | 0/256 | 0/253 | 1/253 | 1/125 | 4/124 |
| Aspartate aminotransferase increasedInvestigations | 0/256 | 0/253 | 2/253 | 3/125 | 4/124 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 0/256 | 0/253 | 4/253 | 1/125 | 4/124 |
| Age, Continuous(years) | CT-P43 | EU-Stelara | Total |
|---|---|---|---|
| Mean | 42.6 ± 13.00 | 42.2 ± 12.64 | 42.4 ± 12.81 |
| Sex: Female, Male(Participants) | CT-P43 | EU-Stelara | Total |
|---|---|---|---|
| Female | 95 | 80 | 175 |
| Male | 161 | 173 | 334 |
| Race (NIH/OMB)(Participants) | CT-P43 | EU-Stelara | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 25 | 23 | 48 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 231 | 230 | 461 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | CT-P43 | EU-Stelara | Total |
|---|---|---|---|
| Estonia | 5 | 6 | 11 |
| South Korea | 25 | 23 | 48 |
| Poland | 189 | 188 | 377 |
| Ukraine | 37 | 36 | 73 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2021 to primary completion in Aug 2021, 6 months.
Results were first posted in Jun 2023, 1 year 10 months after primary completion.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 6 months is below that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.